Royalty Pharma plc (RPRX) stock intrinsic value fair value estimate & owner earnings analysis

Royalty Pharma buys the right to a slice of future sales of already-approved (or near-approved) medicines, in exchange for an upfront payment to the drug's owner. It does not manufacture, market, or sell any drug itself; it collects a contractual royalty on sales that other companies generate. Its portfolio spans royalties on more than 35 marketed medicines across rare disease, neuroscience, oncology, hematology, immunology, respiratory disease and diabetes. No single product accounted for more than about a quarter of collections in 2025, and the largest holding, a royalty on Vertex's cystic fibrosis franchise (Trikafta and related therapies), is expected to retain patent protection into 2037. Across the whole portfolio, the weighted-average remaining royalty life is roughly 13 years. A key accounting point shapes this analysis. Royalties are carried on the balance sheet similarly to a loan: each dollar collected is split between revenue (interest-like income) and a reduction in the carrying value of the royalty (like a loan being paid down). To keep the portfolio from shrinking, the company has to reinvest that 'paydown' portion into new royalty purchases every year; only capital invested beyond that replacement level grows the portfolio. We treated that required reinvestment as a real cost of doing business, alongside stock-based compensation, which is also a genuine cost to shareholders even though it does not consume cash directly. We also excluded the portion of collected cash that is contractually owed to outside partners in a handful of older, legacy royalty structures, since that cash was never available to Royalty Pharma's own shareholders. In May 2025 the company brought its outside investment manager in-house, ending an external arrangement under which it had paid a fee equal to about 6.5% of royalty cash collected. That fee is now gone, but it has been replaced by a materially larger cost of internal compensation, a meaningful share of which is paid in equity (diluting existing shareholders) rather than cash. The first, partial year of this new structure shows total compensation-related costs (cash plus equity) roughly double what the old cash fee cost, and the most recent quarterly filing shows the equity-based portion still rising. This is the single largest swing factor in our estimate of the cash available to owners today, and it is not yet possible to know whether it will settle at a lower run-rate as the initial award finishes phasing in, or continue to climb. We valued the business as a story that runs for the next decade and beyond, not a single formula. The base case assumes underlying cash generation dips further in 2026 as the new compensation structure reaches its first full year, then stabilizes as the initial transition costs fade and the company continues buying new royalties at roughly its long-run historical pace (it has done so, in many separate transactions each year, funded entirely from its own royalty collections, for close to three decades through multiple market cycles). We did not assume any specific new royalty deal beyond what the company had already announced in its most recent annual report. On this basis, the business is worth about $22 per share before debt, and about $8.50 per share after subtracting net debt of roughly $8.3 billion (partly offset by the benefit of a portion of that debt being long-dated and fixed at interest rates well below prevailing levels). The bull case assumes the new compensation cost stabilizes quickly and the company's already-announced 2025 royalty transactions (with combined potential value of about $4.7 billion, of which $2.6 billion had been funded by year-end) pay out largely as planned; on this path the shares are worth roughly $13.90. The bear case assumes the new compensation cost keeps rising faster than collections, as the most recent data suggests it might, and that upcoming debt refinancing happens at materially higher rates than the company's older, cheaper bonds carry, leaving less capital to redeploy into new royalties. On this path, the value of the business itself falls to roughly $8.50 per share before debt, which is less than the roughly $15 per share of net debt on our estimate, meaning shareholders could be left with less than nothing after lenders are paid, by a margin of a few dollars per share. We want to be plain about this: it is our most pessimistic, but not impossible, case, and it does not imply the company would be unable to pay its interest bills, which our model shows it comfortably can even in this scenario. Given the wide range between these outcomes and the genuine uncertainty introduced by last year's change in how the company pays its people, we think a substantial discount to our base-case estimate is warranted before shares would offer an attractive margin of safety.